Pneumonia Testing Market By Test Type (Molecular Diagnostic Tests, Immunological Tests, Microbiological Tests, Serological Tests); By Product Type (Test Kits & Reagents, Instruments, Consumables); By Technology (PCR-Based Testing, Immunoassays, Culture-Based Testing, Other Technologies); By Pathogen Type (Bacterial Pneumonia, Viral Pneumonia, Fungal Pneumonia); By End User (Hospitals, Diagnostic Laboratories, Ambulatory Care Centers, Other End Users); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Rapid Molecular Diagnostics and Hospital Testing Volumes Reshaping the Pneumonia Testing Market? – (Updated On: 8th-Oct-2026)

The Global Pneumonia Testing Market was valued at USD 1.97 billion in 2025 and is projected to reach USD 3.11 billion by 2032, expanding at a CAGR of 6.7% during 2026–2032, according to Strategic Market Research.

 

Pneumonia testing refers to diagnostic tests used to detect lung infections and identify the bacteria or viruses responsible.

 

Pneumonia-related testing activity is substantial in the United States. CDC recorded approximately 1.2 million emergency department visits with pneumonia as the primary diagnosis in 2022. A U.S. study involving 2,251 hospitalized pneumonia patients found that all underwent chest X-rays, while 748 patients (33%) also received chest CT scans. Another study covering 154,799 pneumonia patients across 177 U.S. hospitals reported 143,043 patients receiving blood cultures, 45,878 receiving respiratory cultures, 23,885 undergoing pneumococcal urinary antigen testing, and 32,498 receiving Legionella urinary antigen tests. Respiratory culture testing reached 54.0% among severe pneumonia patients compared with 25.6% among nonsevere cases, indicating greater laboratory testing needs in patients with serious infections.

 

International hospital data also demonstrate the scale of pneumonia-specific diagnostic testing. A study involving 3,702 hospitalized pneumonia patients across 54 countries found that 3,217 patients (86.9%) underwent microbiological testing. Blood cultures were performed in 71.1% of patients, sputum cultures in 61.8%, Legionella urinary antigen testing in 30.1%, and pneumococcal urinary antigen testing in 30.0%. An infection-causing organism was identified in 1,173 patients, representing 36.5% of those tested. These findings reflect substantial use of culture-based tests and antigen assays, creating recurring demand for laboratory reagents, culture media, and diagnostic test kits.

 

Pneumonia-specific molecular diagnostics and rapid pathogen detection represent important areas of technological advancement. bioMérieux's BIOFIRE FILMARRAY Pneumonia Panel can identify 33 targets, including 18 bacteria, 8 viruses, and 7 antibiotic-resistance markers, in approximately one hour. Its Pneumonia Panel plus can detect 34 targets within a similar time. In November 2024, the U.S. FDA cleared updated versions of both panels. Testing for several organisms using a single respiratory sample helps hospitals receive results faster and creates additional demand for molecular testing instruments and disposable PCR cartridges.

 

Overall, the pneumonia testing market is moving toward faster, more accurate, and increasingly automated diagnostics, with hospital testing volumes, molecular technology adoption, and recurring expenditure on reagents supporting revenue growth through 2032.

 

Which Segments Are Leading and Growing Fastest in the Pneumonia Testing Market?

By Test Type: Rapid Molecular Tests Lead Earlier Pathogen Identification

Leading and Fastest-Growing Subsegment – Molecular Diagnostic Tests

Molecular Diagnostic Tests accounted for approximately 42% of the global Pneumonia Testing Market, valued at USD 827 million in 2025, and are projected to register the fastest CAGR of 8.93% during 2026–2032. Their increasing adoption is supported by the ability to rapidly and accurately identify bacterial and viral pathogens responsible for pneumonia. Faster pathogen identification enables healthcare providers to initiate targeted antimicrobial treatment earlier, reducing diagnostic delays and unnecessary antibiotic use. Hospitals and diagnostic laboratories are increasingly adopting molecular testing platforms to improve clinical decision-making and patient outcomes.

 

By Product Type: Test Kits and Reagents Drive Recurring Testing Revenue

Leading and Fastest-Growing Subsegment – Test Kits and Reagents

Test kits and reagents accounted for approximately 58% of the global Pneumonia Testing Market, valued at USD 1.143 billion in 2025, and are projected to record the fastest CAGR of 7.36% during 2026–2032. Their widespread use is supported by the need for rapid and accurate identification of pneumonia-causing pathogens. Modern diagnostic kits can identify specific bacterial and viral infections within minutes to hours, allowing clinicians to initiate appropriate treatment earlier. Increasing adoption of rapid molecular and antigen-based tests is further expanding their clinical importance.

 

By Technology: PCR Accelerates Pathogen Detection and Clinical Decisions

Leading and Fastest-Growing Subsegment – PCR-Based Testing

PCR-Based Testing held an estimated 43% share of the global Pneumonia Testing Market, valued at USD 847 million in 2025, and is projected to register the fastest CAGR of 8.70% during 2026–2032. Its strong market position reflects the increasing use of molecular diagnostics for rapid and accurate identification of bacterial and viral pathogens responsible for pneumonia. Faster pathogen detection helps clinicians select appropriate treatments earlier, while expanding PCR testing capabilities across hospitals and diagnostic laboratories supports wider adoption, particularly in critical care and respiratory infection management.

 

By Pathogen Type: Bacterial Testing Leads as Viral Diagnostics Expand Faster

Leading Subsegment – Bacterial Pneumonia

Bacterial Pneumonia Testing accounted for approximately 51% of the global Pneumonia Testing Market, valued at USD 1.005 billion in 2025, and is projected to expand at a CAGR of 5.60% during 2026–2032. Bacterial pneumonia requires accurate pathogen identification to guide antibiotic treatment and reduce inappropriate prescriptions. Hospitals and diagnostic laboratories increasingly rely on bacterial cultures, molecular diagnostic assays, and rapid pathogen detection tests to support antibiotic stewardship programs. Rising emphasis on targeted treatment and antimicrobial resistance monitoring continues to encourage investment in bacterial pneumonia testing.

Fastest-Growing Subsegment – Viral Pneumonia

Viral Pneumonia Testing accounted for approximately 39% of the global Pneumonia Testing Market, valued at USD 768 million in 2025, and is projected to expand at the fastest CAGR of 8.58% during 2026–2032. Its importance in pneumonia diagnosis is increasing as clinical symptoms and conventional imaging often cannot reliably differentiate viral infections from bacterial pneumonia. Greater use of molecular diagnostics and rapid viral pathogen testing is helping healthcare providers identify infections accurately, guide targeted treatment decisions, avoid unnecessary antibiotic prescriptions, and improve patient management.

 

By End User: Hospitals Anchor Testing as Diagnostic Laboratories Expand

Leading Subsegment – Hospitals

Hospitals dominated the Pneumonia Testing Market with an estimated 55% market share, valued at USD 1.083 billion in 2025, and are projected to expand at a CAGR of 6.50% during 2026–2032. Hospitals serve as major centers for comprehensive pneumonia diagnosis, particularly for patients with severe respiratory infections, complex medical conditions, or complications requiring hospitalization. Their access to molecular diagnostics, microbiological testing, and advanced imaging supports accurate pathogen identification and timely clinical decisions, contributing to sustained spending on hospital-based pneumonia testing services.

Fastest-Growing Subsegment – Diagnostic Laboratories

Diagnostic laboratories accounted for an estimated 32% share of the Pneumonia Testing Market, valued at USD 630 million in 2025, and are projected to register the fastest CAGR of 7.58% during 2026–2032. Their leading position reflects the increasing use of laboratory-based testing to identify bacterial, viral, and atypical pathogens responsible for pneumonia. Diagnostic laboratories also assess infection severity and provide accurate test results that help clinicians select targeted antimicrobial treatments, encouraging wider adoption of molecular diagnostics, pathogen identification assays, and automated pneumonia testing platforms.

 

By Geography: North America Leads as Asia Pacific Accelerates

Leading Subsegment – North America

North America accounted for approximately 38% of the global Pneumonia Testing Market, valued at USD 749 million in 2025, and is projected to expand at a CAGR of 5.80% during 2026–2032. Pneumonia testing practices across the region are shifting toward rapid molecular diagnostics and high-precision testing methods. Hospitals and diagnostic laboratories are increasingly adopting advanced testing platforms to identify respiratory pathogens faster and improve clinical decisions. Wider access to multiplex PCR testing and automated diagnostic systems is also encouraging healthcare providers to modernize existing testing capabilities.

Fastest-Growing Subsegment – Asia Pacific

Asia-Pacific accounted for approximately 26% of the global Pneumonia Testing Market in 2025, valued at USD 512 million, and is projected to record the fastest regional CAGR of 8.75% during 2026–2032. Expanding hospital networks, increasing pneumonia-related hospitalizations, and wider access to diagnostic laboratories are encouraging greater use of pneumonia testing across the region. Countries such as China, India, and Japan are investing in molecular diagnostics and rapid testing technologies to improve early detection, creating opportunities for diagnostic equipment manufacturers and testing service providers.

 

How Is bioMérieux Strengthening Its Competitive Position in the Global Pneumonia Testing Market?

bioMérieux – BIOFIRE Pneumonia Panels Strengthen Its Molecular Testing Position

bioMérieux is a leading company in specialized molecular pneumonia testing, supported by its BIOFIRE FILMARRAY Pneumonia Panels. These panels identify up to 34 bacterial, viral, and antimicrobial resistance targets in approximately one hour, helping hospitals identify infectious agents and support treatment decisions. The company reported EUR 4.07 billion in total sales in 2025, while its BIOFIRE respiratory panel sales increased by 1% organically. Its established molecular testing portfolio and hospital laboratory presence position it strongly in the premium pneumonia diagnostics segment, although its precise global pneumonia testing market share is not publicly disclosed.

Other Major Companies and Their Market Roles:

• Abbott Laboratories: Supplies BinaxNOW Streptococcus pneumoniae antigen tests, delivering results in approximately 15 minutes and supporting rapid pneumococcal pneumonia diagnosis in healthcare facilities.

• Thermo Fisher Scientific: Provides Applied Biosystems TrueMark respiratory pathogen panels and PCR testing technologies that support laboratory detection of pneumonia-associated bacteria and respiratory viruses.

 

Analyst Commentary: How Will Multiplex Testing and Automation Shape the Next Phase of Pneumonia Diagnostics?

The pneumonia testing market is shifting toward faster, more accurate, and comprehensive diagnostic solutions as hospitals prioritize early pathogen identification and timely treatment decisions. Key growth opportunities are emerging in multiplex PCR testing, rapid point-of-care diagnostics, automated molecular platforms, and antimicrobial resistance detection. Rising demand for tests that distinguish bacterial from viral infections is encouraging investment in integrated diagnostic systems that reduce turnaround times, support targeted antibiotic use, and improve laboratory efficiency.

 

Pneumonia Testing Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.97 Billion
Revenue Forecast in 2032	USD 3.11 Billion
Overall Growth Rate	CAGR of 6.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Test Type, By Product Type, By Technology, By Pathogen Type, By End User, By Geography
By Test Type	Molecular Diagnostic Tests, Immunological Tests, Microbiological Tests, Serological Tests
By Product Type	Test Kits and Reagents, Instruments, Consumables
By Technology	PCR-Based Testing, Immunoassays, Culture-Based Testing, Other Technologies
By Pathogen Type	Bacterial Pneumonia, Viral Pneumonia, Fungal Pneumonia
By End User	Hospitals, Diagnostic Laboratories, Ambulatory Care Centers, Other End Users
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	High pneumonia-related hospital and emergency-care volumes, increasing demand for rapid pathogen identification, rising adoption of multiplex PCR and molecular diagnostics, growing need to distinguish bacterial from viral infections, antimicrobial stewardship requirements, expansion of automated laboratory testing, and increasing demand for faster diagnostic turnaround times
Customization Option	Available upon request